Stargardt Disease Therapeutics Market, By Drug Type (Emixustat, LBS-008), By Age Group (Children (Below17 Years), Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies  Online Pharmacies), By Region (North America, Latin

Stargardt Disease Therapeutics Market, By Drug Type (Emixustat, LBS-008), By Age Group (Children (Below17 Years), Adult (Above 17 Years)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies  Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Stargardt disease also called Stargardt's macular dystrophy (SMD) that affects approximately one in 10,000 people and described as central vision loss early in life. Stargardt Disease is most commonly caused by mutations in the ABCA4 gene located on chromosome 1 and is inherited in an autosomal recessive manner. This disorder affects the specialized light-sensitive tissue present in the retina. This type of macular degeneration affects the center of the retina which is known as macula which adds sharpness to the central vision. The affected individuals also show the symptoms of color blindness. The signs and symptoms appear in late childhood which is responsible for disease progression.
Market Dynamics
The increasing prevalence of stargardt disease is expected to drive the market growth over the forecast period. For instance, according to the article published in the Association for Research in Vision and Ophthalmology journal, the worldwide prevalence of stargardt disease is estimated to be in between 1 in 8,000 to 10,000 individuals.
Furthermore, key players operating in the Global Stargardt Disease Therapeutics Market are focusing on adoption of growth strategies are expected to drive the market growth during the forecast period. For instance, in July 2017, Ophthotech Corporation, a clinical stage company, is adopting a new strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for which there are limited or no treatment options available. Ophthotech’s orphan ophthalmic disease strategy will be led by a randomized, controlled clinical trial assessing the efficacy and safety of Zimura (avacincaptad pegol), the company’s C5 complement inhibitor, for Stargardt disease.
Key features of the study:
This report provides in-depth analysis of the Global Stargardt Disease Therapeutics Market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Global Stargardt Disease Therapeutics Market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc, Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd., ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., F. Hoffmann-La Roche AG.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The Global Stargardt Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Stargardt Disease Therapeutics Market .
Detailed Segmentation:
Global Stargardt Disease Therapeutics Market , By Drug Type:
Emixustat
LBS-008
Global Stargardt Disease Therapeutics Market , By Age Group:
Children (Below17 Years)
Adult (Above 17 Years)
Global Stargardt Disease Therapeutics Market , By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Stargardt Disease Therapeutics Market , By Region:
North America
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Emixustat
LBS-008
By Age Group
Children (Below17 Years)
Adult (Above 17 Years)
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
South Africa
Central Africa
North Africa
Company Profiles
Kubota Pharmaceutical Holdings Co., Ltd.*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Stargazer Pharmaceuticals Inc.
Iveric Bio, Inc.
Sanofi S.A.
Alkeus Pharmaceuticals Inc.
Astellas Pharma Inc.
CHABiotech CO., Ltd
ReVision Therapeutics, Inc.
Lin BioScience, Inc.
Biogen Inc.
F. Hoffmann-La Roche AG

“*” marked represents similar segmentation in other categories in the respective section.